Lupin Limited’s Board of Directors approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025, on February 12, 2026. Standalone revenue from operations reached ₹45,011.9 million for the quarter and ₹142,780.6 million year-to-date. Consolidated Net Profit After Tax stood at ₹7,115.7 million for the quarter and ₹41,792.8 million for the nine months ended.
Unaudited Financial Results for Q3 FY26 Approved
The Board of Directors of Lupin Limited convened a meeting on Thursday, February 12, 2026, and unanimously approved the Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2025. The meeting commenced at 06:30 p.m. (IST) and concluded at 08:40 p.m. (IST).
Standalone Financial Performance Summary (in million)
For the quarter ended December 31, 2025, key standalone figures were:
- Total Revenue from operations: ₹45,011.9
- Profit before tax (after exceptional items): ₹8,679.4
- Net Profit After Tax: ₹7,174.5
- Total Comprehensive Income/(Loss), net of tax: ₹7,115.7
For the nine months ended December 31, 2025, the standalone results showed:
- Total Revenue from operations: ₹142,780.6
- Profit before tax (after exceptional items): ₹48,371.2
- Net Profit After Tax: ₹39,729.6
- Total Comprehensive Income/(Loss), net of tax: ₹39,584.9
Key Notes Affecting Standalone Results
Exceptional Items
The results for the quarter and nine months reflect significant exceptional items:
- A provision of ₹4,493.9 million (USD 50.0 million) was created related to Antitrust Litigations in the US.
- A provision of ₹1,348.1 million (USD 15.0 million) was recognized for a one-time payment related to a settlement agreement with Astellas concerning Mirabegron ER Tablets.
- Incremental cost recognition of ₹496.4 million due to the implementation of the New Labour Codes in India.
- Gain on divestment from the transfer of OTC and API R&D business, amounting to ₹6,589.6 million for the quarter and ₹6,626.8 million (aggregate) for nine months.
- A provision for diminution in the value of investment in a subsidiary amounting to ₹700.0 million was recorded.
Share Allotment
During the quarter ended December 31, 2025, 40,938 fully paid-up equity shares were allotted upon exercise of ESOPs, increasing share capital by ₹0.1 million.
Consolidated Financial Performance Summary (in million)
The Consolidated Financial Results indicate:
- Quarter Ended 31/12/2025 Revenue from operations: ₹71,675.2
- Quarter Ended 31/12/2025 Profit/(Loss) after tax: ₹11,805.1
- Nine Months Ended 31/12/2025 Revenue from operations: ₹227,079.0
- Nine Months Ended 31/12/2025 Profit/(Loss) after tax (attributable to Owners of the Company): ₹38,725.2
Consolidated Exceptional Items
The consolidated figures include specific exceptional adjustments:
- An exceptional provision of ₹4,265.7 million recognized during the nine months ended December 31, 2025.
- For the quarter, exceptional income of ₹603.2 million was recognized from an arbitration award, alongside a reversal of expense provision of ₹611.6 million.
- The group recorded a settlement income of ₹873.7 million during the nine months.
Segmental Performance Highlights (Consolidated)
Revenue
Pharmaceuticals remained the dominant segment, reporting revenue of ₹71,308.9 million for the quarter and ₹226,043.1 million for the nine months ended December 31, 2025.
Profit Before Tax (After Exceptional Items)
Profit before tax for the Pharmaceuticals segment was ₹15,673.5 million for the quarter and ₹41,608.1 million for the nine months ended December 31, 2025. The ‘Others’ segment reflected a loss before tax of ₹(453.1 million) for the quarter.
Auditor Review Conclusion
The results were subjected to a Limited Review by BSR & Co. LLP, Chartered Accountants. The report confirms that, based on the review procedures performed, nothing has come to the auditor’s attention that causes them to believe the accompanying Statement is not prepared in accordance with applicable standards and regulations or contains any material misstatement.
Source: BSE
